Fig. 3.
Safety of CHM compared with α2-adrenergic agonists. Summary estimates of the relative risks (RRs) and their 95% CIs are shown for each of the five most commonly reported adverse effects. All RRs were analyzed in random-effects models. NR indicates the fail-safe number, i.e. the number of unpublished negative studies that would be required to overturn each significant finding at an alpha level of 0.05
